New drug cocktail targets Hard-to-Treat pancreatic cancer
NCT ID NCT02985125
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tested a combination of two oral drugs, ribociclib and everolimus, in 12 people with metastatic pancreatic cancer that had stopped responding to standard chemotherapy. The goal was to see if the combination could slow tumor growth. Participants took the drugs daily in 28-day cycles. The trial was early-stage and aimed to find the right dose and check for signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ribociclib and everolimus
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced pancreatic cancer that has stopped responding to standard chemotherapy.
What could go wrong
This was a very small, early-phase trial (12 people). The combination may not work well enough or could cause significant side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.